pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Endocrinology & Metabolism · news · pharmadog
← back to Endocrinology & Metabolism
News · Endocrinology & Metabolism
335
stories
2d
Foghorn cuts 40% of workforce
biospace
2d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
2d
#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
endpoints
3d
Top journal’s special issue on women’s health casts spotlight on menopause and pain
stat
3d
3 takeaways from a European obesity scientific meeting
biopharma dive
3d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
3d
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
3d
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
4d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
4d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
4d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
5d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
5d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
6d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
6d
FDA Approves First Treatment for MCT8 Deficiency
fda press
6d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
7d
Regenerative medicine needs more than stem cells
biospace
9d
Federal judge rolls back landmark disability protections
stat
9d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
9d
At least five candidates vie to become the next WHO leader, as questions over U.S. role loom
stat
10d
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
10d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
10d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
10d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
11d
New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption
fiercebiotech
11d
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
11d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
12d
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
12d
Viking shares surge on updated obesity drug data
biopharma dive
12d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
← prev
page 1 of 12
next →
